Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
SNYDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 12, 2025 | $2.20 | 2025-05-09 | 2025-05-09 |
| June 6, 2024 | $2.04 | 2024-05-09 | 2024-05-10 |
| June 23, 2023 | $1.90 | 2023-05-30 | 2023-05-31 |
| May 31, 2022 | $1.75 | 2022-05-04 | 2022-05-05 |
| May 26, 2021 | $1.93 | 2021-05-03 | 2021-05-04 |
Dividends Summary
- Sanofi American Depositary Shares (Each representing one-half of one ordinary share) has issued 18 dividend payments over the past 17 years
- The most recent dividend was paid 191 days ago, on June 12, 2025
- The highest dividend payed out to investors during this period was $2.20 per share
- The average dividend paid during this period was $1.76 per share.
Company News
Cytokinetics announced FDA approval of MYQORZO (aficamten), a cardiac myosin inhibitor for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approval is based on the SEQUOIA-HCM Phase 3 trial, which demonstrated significant improvements in exercise capacity and symptom relief. The drug will be available in the U.S. in the s...
Sanofi has expanded its partnership with Dren Bio to develop next-generation B-cell depleting therapies for autoimmune diseases, offering an upfront payment of $100 million and potential milestone payments up to $1.7 billion.
Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.
Regeneron Pharmaceuticals reported better-than-expected Q2 results, driven by growth in Eylea HD, Dupixent, and Libtayo. However, Eylea sales declined due to increased competition. The company's pipeline progress was mixed, with a delay in the FDA decision for linvoseltamab and a three-month extension for the Dupixent COPD indication.
JMP Securities initiated coverage on Inhibrx Inc. with a Market Perform rating following the acquisition of INBRX-101 by Sanofi. The newly formed Inhibrx Biosciences has a strong financial foundation, but faces challenges with negative profitability metrics.
